Kristel M L Crommentuyn
Overview
Explore the profile of Kristel M L Crommentuyn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ter Heine R, Scherpbier H, Crommentuyn K, Bekker V, Beijnen J, Kuijpers T, et al.
Antivir Ther
. 2008 Oct;
13(6):779-87.
PMID: 18839779
Background: Our main objectives were to study the population pharmacokinetics of efavirenz and to explore the adequacy of dosing guidelines. Methods: A total of 33 HIV-1-infected patients were recruited from...
2.
Sankatsing S, Cornelissen M, Kloosterboer N, Crommentuyn K, Bosch T, Mul F, et al.
AIDS Res Hum Retroviruses
. 2007 Feb;
23(1):19-27.
PMID: 17263628
P-glycoprotein (P-gp) can compromise the antiretroviral effect of a protease inhibitor (PI)-containing regimen for HIV-1, but can also reduce HIV-1 replication. We studied the net effect of P-gp on the...
3.
Sparidans R, Dost F, Crommentuyn K, Huitema A, Schellens J, Beijnen J
Biomed Chromatogr
. 2006 Jun;
20(8):671-3.
PMID: 16799929
Tipranavir is the most recently introduced protease inhibitor for the suppression of the human immunodeficiency virus (HIV). A selective reversed-phase liquid chromatographic assay, previously developed for atazanavir, has been extended...
4.
Crommentuyn K, Scherpbier H, Kuijpers T, Mathot R, Huitema A, Beijnen J
Pediatr Infect Dis J
. 2006 May;
25(6):538-43.
PMID: 16732153
Background: The objectives of this study are to develop and validate a population pharmacokinetic model that adequately describes the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected children;...
5.
Sparidans R, Dost F, Crommentuyn K, Huitema A, Schellens J, Beijnen J
Biomed Chromatogr
. 2005 Jun;
20(1):72-6.
PMID: 15954163
Atazanavir is the most recently introduced protease inhibitor for the suppression of the anti-human immunodeficiency virus. A sensitive and selective reversed-phase liquid chromatographic assay for this drug in human plasma...
6.
Kappelhoff B, Huitema A, Crommentuyn K, Mulder J, Meenhorst P, van Gorp E, et al.
Br J Clin Pharmacol
. 2005 Jan;
59(2):174-82.
PMID: 15676039
Aims: The aim of this study was to develop and validate a population pharmacokinetic model of ritonavir, used as an antiviral agent or as a booster, in a large patient...
7.
Crommentuyn K, Mulder J, Mairuhu A, van Gorp E, Meenhorst P, Huitema A, et al.
Antivir Ther
. 2004 Nov;
9(5):779-85.
PMID: 15535416
Therapeutic drug monitoring of protease inhibitors (PIs) is usually performed on plasma samples although their antiretroviral effect takes place inside cells. Little is known, however, about the intracellular accumulation and...
8.
Kappelhoff B, Crommentuyn K, de Maat M, Mulder J, Huitema A, Beijnen J
Clin Pharmacokinet
. 2004 Oct;
43(13):845-53.
PMID: 15509183
Several relationships have been reported between antiretroviral drug concentrations and the efficacy of treatment, and toxicity. Therefore, therapeutic drug monitoring (TDM) may be a valuable tool in improving the treatment...
9.
Sankatsing S, Hoggard P, Huitema A, Sparidans R, Kewn S, Crommentuyn K, et al.
Clin Pharmacokinet
. 2004 Sep;
43(12):823-32.
PMID: 15355127
Objective: To study the effect of mycophenolate mofetil therapy on the pharmacokinetic parameters of a number of antiretroviral drugs, on intracellular pools of deoxycytidine triphosphate (dCTP) and deoxyguanosine triphosphate (dGTP),...
10.
Crommentuyn K, Mulder J, Sparidans R, Huitema A, Schellens J, Beijnen J
Clin Infect Dis
. 2004 Apr;
38(8):e73-5.
PMID: 15095234
We describe a drug-drug interaction between coformulated lopinavir/ritonavir and itraconazole in a patient infected with human immunodeficiency virus type 1 who had disseminated histoplasmosis. Coadministration of these agents led to...